The pharmaceutical industry has long relied on costly and extensive clinical testing methods for new drugs, including animal testing. However, these methods often lead to increased failures during human testing, as animals are not always accurate predictors of human success. In response, regulatory bodies like the FDA and global regulators are reevaluating clinical trial standards, aiming to minimize the use of animal testing. This shift has created a need for an alternative solution.
Quris-AI is disrupting the pharmaceutical industry with its innovative Bio-AI platform, which combines cutting-edge artificial intelligence with organs-on-chip technology. By integrating their scientific and biological expertise with AI capabilities, Quris-AI can now more accurately predict the safety of drugs in humans.
The Bio-AI platform comprises artificial intelligence and organs on chips technology, revolutionizing the development of newer, faster, and safer medicines. Testing is conducted exclusively on human tissue, allowing for the evaluation of thousands of compounds within a short timeframe. Miniature human organs are placed on chips smaller than a millimeter in size, enabling researchers to understand how different drugs affect the human body.
This approach has not only the potential to save pharmaceutical companies valuable time but also reduce costs associated with traditional clinical trials. Additionally, the Bio-AI platform takes into account the variations between individuals, ensuring more tailored and accurate predictions and assessments. By combining advanced technology with a deep understanding of biology, Quris is leading the way towards faster, safer, and more human-centric drug development.
Watch the video below to learn more: